Pharmacology and therapeutic effects of nicorandil
- 1 August 1990
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 4 (4), 1075-1088
- https://doi.org/10.1007/bf01856503
Abstract
Nicorandil, a nicotinamide derivative, is an orally efficacious antianginal drug possessing a nitrate moiety in its chemical structure. This drug is an effective and welltolerated treatment for various types of angina pectoris. Its general efficacy is similar to that of nitrates, with several unique effects on the cardiovascular system. Nicorandil causes sustained dilation of both the arterial resistance and conductive vessels, thus markedly dilating the coronary artery and increasing coronary blood flow. In addition, nicorandil, unlike nitroglycerin or isosorbide dinitrate, possesses little hemodynamic effect on heart rate, blood pressure, or cardiac contractility with clinical doses yielding antianginal effects. The mechanism causing coronary vasodilation has not been completely clarified but appears to be associated partly with increases in c-GMP, as well as the hyperpolarization of the smooth muscle membrane. Nicorandil, in single oral doses of 10–30 mg, has been shown to be effective in chronic stable angina, as assessed objectively by increases in exercise duration and/or the time to onset of ST-segment depression during treadmill exercise. In open studies and controlled efficacy evaluations, nicorandil in daily oral doses of 15–40 mg demonstrated significant effectiveness in the treatment of various types of angina pectoris. Headaches due to vasodilation may occur, and some side effects occurred in 5.1–34% of patients receiving nicorandil, but were generally minor in nature. There was not depressant effect on atrioventricular conduction, which occurs frequently in patients treated with calcium antagonists of the verapamil and diltiazem type. Nicrorandil may be effective even in patients with rest and effort angina who do not respond to combination therapy with calcium antagonists and oral nitrates. Thus, nicorandil appears to be a valuable addition to the arsenal of antianginal drugs due to its low incidence of serious side effects.This publication has 103 references indexed in Scilit:
- Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart FailureThe New England Journal of Medicine, 1987
- Nicorandil releases acetylcholine-induced sustained coronary arterial constriction in monkeys and baboons.Japanese Heart Journal, 1984
- Atrioventricular Dissociation and Sinus Arrest Induced by Oral DiltiazemThe New England Journal of Medicine, 1983
- SG-75 induction of increased coronary outflow and PGE1 from ischemic areas in dogs with experimental myocardial infarction.Japanese Heart Journal, 1982
- The mechanisms of nitroglycerin action: stenosis vasodilatation as a major component of the drug response.Circulation, 1981
- New Experimental Congenital Diabetic Mice (N. S. Y. Mice)The Tohoku Journal of Experimental Medicine, 1980
- Effect of 2-Nicotinamidethyl Nitrate (SG 75) on Coronary CirculationJapanese Heart Journal, 1978
- Role of Autonomic Nervous System in the Pathogenesis of Prinzmetal's Variant Form of AnginaCirculation, 1974
- Importance of the Design of an Exercise Protocol in the Evaluation of Patients with Angina PectorisCirculation, 1971
- The hemodynamic determinants of the rate of change in pressure in the left ventricle during isometric contractionAmerican Heart Journal, 1960